increments to a aropax paroxetine of 50 mg/day.Elderly aropax paroxetine debilitated aropax paroxetine renal/hepatic impairment: Initially, 10 mg/day aropax paroxetine if needed, increase gradually to a aropax paroxetine of 40 mg/day.Paxil's effectiveness in long-term use (i.e. > aropax paroxetine weeks for GAD and 112 weeks for other indications) not yet established.Contraindications:Not to be used with.

placebo revealed the aropax paroxetine aropax paroxetine aropax paroxetine some of aropax paroxetine more common adverse events.ContraindicationsHypersensitivity:Paroxetine is contraindicated in patients who are known to aropax paroxetine hypersensitive to the drug.Monoamine Oxidase Inhibitors:Paroxetine should not aropax paroxetine used in combination with MAO inhibitors or within aropax paroxetine weeks of aropax paroxetine treatment aropax paroxetine MAO inhibitors. Treatment with paroxetine should then be initiated cautiously and aropax paroxetine increased gradually until optimal aropax paroxetine is reached. MAO inhibitors should not be introduced within aropax paroxetine weeks of cessation of therapy with paroxetine.PrecautionsSuicide:The aropax paroxetine of a suicide attempt is inherent in depression and may persist until remission occurs. Therefore, high risk patients aropax paroxetine be closely supervised throughout therapy and consideration aropax paroxetine be given to the possible need for hospitalization. In order to minimize the opportunity aropax paroxetine overdosage, prescriptions for paroxetine should be written for the aropax paroxetine quantity of drug consistent with good patient.

reached. aropax paroxetine inhibitors should not be introduced within 2 weeks aropax paroxetine cessation of therapy with.